Suspension of trading

Income Statement Valerio Therapeutics Börse Stuttgart

Stocks

C4X

FR0010095596

Pharmaceuticals

Real-time Estimate Tradegate Other stock markets 10:17:59 31/07/2026 +04			5-day change	1st Jan Change
0.7490 ^EUR	+1,287.04%		+56.98%	-11.91%

07-16	Valerio Therapeutics, Abivax Enter R&D Collaboration for Inflammatory Disease Therapies	MT
07-16	Valerio Therapeutics, Abivax Sign R&D Deal for Inflammatory Diseases' Drug Candidates	MT

ce0676229b0a40f76bb1603729c.uie1E3coqjrSGJ4Q4NeSPK3FJlSi-HIt2uRS3Fze8ZA.1mGCSzVG6WO9KOt9jLajXvm0bzXhq0VIvoE-gxSzpeXcEYElOGDgfOFc7Q

Published financial data: VALERIO THERAPEUTICS

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2021	2022	2023	2024	2025
Revenues	4.06M	1.44M	1.8M	1.79M	2.57M
Other Revenues, Total	-	-	-	-	-
Total Revenues	4.06M	1.44M	1.8M	1.79M	2.57M
Cost of Goods Sold, Total	368K	514K	533K	513K	847K
Gross Profit	3.69M	929K	1.27M	1.28M	1.73M
Selling General & Admin Expenses, Total	8.12M	18.02M	19.57M	13.95M	4.68M
Depreciation & Amortization - (IS)	468K	1K	480K	3.26M	1.18M
Other Operating Expenses	693K	25K	272K	560K	-3.59M
Other Operating Expenses, Total	9.28M	18.04M	20.32M	17.77M	2.28M
Operating Income	-5.58M	-17.11M	-19.05M	-16.49M	-550K
Interest Expense, Total	-848K	-2.19M	-138K	-	-281K
Interest And Investment Income	8K	16K	172K	484K	86K
Net Interest Expenses	-840K	-2.17M	34K	484K	-195K
Income (Loss) On Equity Invest.	-	-	-	-8.02M	-3.8M
Currency Exchange Gains (Loss)	-	-279K	-	-	-
Other Non Operating Income (Expenses)	146K	-101K	-74K	-312K	-97K
EBT, Excl. Unusual Items	-6.28M	-19.67M	-19.09M	-24.34M	-4.64M
Impairment of Goodwill	-	-	-	-	-
Gain (Loss) On Sale Of Investments	-	-	-	-	-
Asset Writedown	-	-	-	-	-
Legal Settlements	-	-	-	-	-
Other Unusual Items	439K	389K	-1.23M	787K	-
EBT, Incl. Unusual Items	-5.84M	-19.28M	-20.33M	-23.55M	-4.64M
Income Tax Expense	100K	285K	17K	377K	261K
Earnings From Continuing Operations	-5.94M	-19.56M	-20.34M	-23.93M	-4.9M
Net Income to Company	-5.94M	-19.56M	-20.34M	-23.93M	-4.9M
Net Income - (IS)	-5.94M	-19.56M	-20.34M	-23.93M	-4.9M
Net Income to Common Incl Extra Items	-5.94M	-19.56M	-20.34M	-23.93M	-4.9M
Net Income to Common Excl. Extra Items	-5.94M	-19.56M	-20.34M	-23.93M	-4.9M
Per Share Items
Net EPS - Basic	-0.07	-0.18	-0.15	-0.16	-0.02
Basic EPS - Continuing Operations	-0.07	-0.18	-0.15	-0.16	-0.02
Basic Weighted Average Shares Outstanding	88.21M	106M	135M	154M	274M
Net EPS - Diluted	-0.07	-0.18	-0.15	-0.16	-0.02
Diluted EPS - Continuing Operations	-0.07	-0.18	-0.15	-0.16	-0.02
Diluted Weighted Average Shares Outstanding	88.21M	106M	135M	154M	274M
Normalized Basic EPS	-0.04	-0.12	-0.09	-0.1	-0.01
Normalized Diluted EPS	-0.04	-0.12	-0.09	-0.1	-0.01
Supplemental Items
EBITDA	-5.54M	-17.04M	-18.92M	-3.9M	3.45M
EBITA	-5.58M	-17.11M	-19.05M	-4.2M	3.25M
EBIT	-5.58M	-17.11M	-19.05M	-16.49M	-550K
Total Revenues (As Reported)	4.06M	-	-	-	-
Effective Tax Rate - (Ratio)	-1.71	-1.48	-0.08	-1.6	-5.63
Current Foreign Taxes	-111K	489K	221K	377K	-
Total Current Taxes	-111K	489K	221K	377K	261K
Deferred Foreign Taxes	211K	-204K	-204K	-	-
Total Deferred Taxes	211K	-204K	-204K	-	-
Normalized Net Income	-3.92M	-12.29M	-11.93M	-15.21M	-2.9M
Interest on Long-Term Debt	-	-	-	-	-
Non-Cash Pension Expense	43K	353K	-	-	-
Supplemental Operating Expense Items
Research And Development Expense From Footnotes	4.9M	11.05M	-	5.14M	578K
Stock-Based Comp., SG&A Exp. (Total)	224K	724K	510K	390K	72K
Stock-Based Comp., Other (Total)	-	-	4K	-	-
Total Stock-Based Compensation	224K	724K	514K	390K	72K

Fiscal Period: December	2021	2022	2023	2024	2025
Assets
Cash And Equivalents	17.89M	14.59M	6.82M	1.18M	1.05M
Short Term Investments	-	-	-	-	-
Total Cash And Short Term Investments	17.89M	14.59M	6.82M	1.18M	1.05M
Accounts Receivable, Total	8.53M	1.47M	1.89M	1.72M	1.94M
Other Receivables	2.27M	3.78M	2.99M	1.67M	1.64M
Total Receivables	10.8M	5.25M	4.88M	3.39M	3.57M
Inventory	-	-	-	-	-
Prepaid Expenses	1.45M	289K	1.17M	-	154K
Other Current Assets, Total	-1K	454K	128K	-	-
Total Current Assets	30.13M	20.58M	13M	4.57M	4.78M
Gross Property Plant And Equipment	6.96M	5.82M	5.94M	6.17M	5.94M
Accumulated Depreciation	-4.72M	-3.94M	-4.41M	-5M	-4.68M
Net Property Plant And Equipment	2.24M	1.89M	1.53M	1.17M	1.26M
Long-term Investments	-	-	-	-	-
Goodwill	18.06M	18.06M	18.06M	11.97M	8.17M
Other Intangibles, Total	0	0	0	-3.26M	-3.26M
Deferred Charges Long-Term	2.47M	2.47M	2.47M	3.26M	3.26M
Other Long-Term Assets, Total	162K	89K	219K	221K	1.02M
Total Assets	53.06M	43.09M	35.27M	17.93M	15.23M
Liabilities
Accounts Payable, Total	2.83M	3.45M	2.46M	5.25M	2.28M
Accrued Expenses, Total	593K	1.81M	2.62M	1.71M	849K
Short-term Borrowings	-	46K	2M	3.13M	705K
Current Portion of Long-Term Debt	2.95M	1M	1.45M	7.3M	915K
Current Portion of Leases	471K	335K	332K	325K	161K
Current Income Taxes Payable	214K	484K	579K	627K	943K
Unearned Revenue Current, Total	-	-	-	-	-
Other Current Liabilities	-	20K	1.69M	-	447K
Total Current Liabilities	7.06M	7.15M	11.13M	18.34M	6.3M
Long-Term Debt	5.08M	8.1M	6.91M	5.63M	6.23M
Long-Term Leases	1.43M	646K	313K	182K	300K
Unearned Revenue Non Current	-	-	-	-	-
Pension & Other Post Retirement Benefits	607K	168K	108K	34K	43K
Deferred Tax Liability Non Current	204K	-	-	-	-
Other Non Current Liabilities	5.74M	4.75M	2.01M	2.01M	280K
Total Liabilities	20.12M	20.82M	20.47M	26.19M	13.16M
Common Stock, Total	23M	27.88M	38.59M	21.61M	4.99M
Additional Paid In Capital	24.58M	27.7M	28.99M	15.69M	29.12M
Retained Earnings	-5.94M	-19.56M	-53.14M	-46.51M	-31.94M
Treasury Stock	-181K	-81K	-61K	-36K	-
Comprehensive Income and Other	-8.52M	-13.67M	425K	310K	-102K
Total Common Equity	32.94M	22.27M	14.8M	-8.93M	2.08M
Minority Interest	-	-	-	665K	-
Total Equity	32.94M	22.27M	14.8M	-8.26M	2.08M
Total Liabilities And Equity	53.06M	43.09M	35.27M	17.93M	15.23M
Supplemental Items
ECS Total Shares Outstanding on Filing Date	111M	111M	154M	154M	499M
ECS Total Common Shares Outstanding	91.57M	111M	154M	154M	499M
Book Value / Share	0.36	0.2	0.1	-0.06	0
Tangible Book Value	14.88M	4.21M	-3.25M	-17.64M	-2.84M
Tangible Book Value Per Share	0.16	0.04	-0.02	-0.11	-0.01
Total Debt	9.93M	10.13M	11M	16.56M	8.31M
Net Debt	-7.95M	-4.45M	4.18M	15.38M	7.26M
Debt Equivalent of Unfunded Proj. Benefit Obligation	607K	168K	108K	34K	43K
Minority Interest, Total (Incl. Fin. Div)	-	-	-	665K	-
Equity Method Investments, Total	-	-	-	-	-
Account Code - Inventory Valuation	6	6	6	6	6
Inventories - Finished Goods, Total	-	-	-	-	-
Machinery, Total	1.34M	-	-	-	-
Full Time Employees	25	25	19	38	25

Fiscal Period: December	2021	2022	2023	2024	2025
Net Income	-5.94M	-19.56M	-20.34M	-23.93M	-4.9M
Depreciation & Amortization - CF	591K	526K	477K	689K	632K
Amortization of Goodwill and Intangible Assets - (CF)	7K	4K	-	12.29M	3.8M
Depreciation & Amortization, Total	598K	530K	477K	12.98M	4.43M
Amortization of Deferred Charges, Total - (CF)	-	-	-	-	-
(Gain) Loss From Sale Of Asset	-	-	-	-787K	-
Asset Writedown & Restructuring Costs	-182K	213K	-	-	-
(Income) Loss On Equity Investments - (CF)	-	-	-	-	-
Stock-Based Compensation (CF)	224K	724K	514K	390K	72K
Other Operating Activities, Total	861K	1.78M	1.42M	2.98M	1.04M
Change in Other Net Operating Assets	-4.14M	6.88M	-665K	-4.09M	1.19M
Cash from Operations	-8.57M	-9.44M	-18.6M	-12.46M	1.84M
Capital Expenditure	-139K	-488K	-183K	-319K	-1.32M
Sale of Property, Plant, and Equipment	-	-	-	-	-
Divestitures	-	-	-	-1.08M	-
Investment in Marketable and Equity Securities, Total	73K	80K	7K	9K	154K
Other Investing Activities, Total	-	-1K	-1K	1K	-
Cash from Investing	-66K	-409K	-177K	-1.39M	-1.16M
Short Term Debt Issued, Total	-	-	-	-	-
Long-Term Debt Issued, Total	3.11M	-	-	-	-
Total Debt Issued	3.11M	-	-	-	-
Long-Term Debt Repaid, Total	-487K	-1.51M	-1.22M	-1.36M	-813K
Total Debt Repaid	-487K	-1.51M	-1.22M	-1.36M	-813K
Issuance of Common Stock	9.35M	7.97M	12.11M	24K	36K
Repurchase of Common Stock	-	-	-125K	-	-
Other Financing Activities, Total	4K	2K	-7K	5.54M	3K
Cash from Financing	11.98M	6.46M	10.76M	4.21M	-774K
Foreign Exchange Rate Adjustments	25K	87K	244K	-115K	-2K
Miscellaneous Cash Flow Adjustments	-	1K	-	4.09M	-
Net Change in Cash	3.36M	-3.3M	-7.77M	-5.66M	-101K
Supplemental Items
Levered Free Cash Flow	-7.36M	-2.92M	-9.79M	5.77M	-736K
Unlevered Free Cash Flow	-6.83M	-1.55M	-9.7M	5.77M	-561K
Change In Net Working Capital	4.02M	-8.38M	-1.4M	-3.03M	3.4M
Net Debt Issued / Repaid	2.62M	-1.51M	-1.22M	-1.36M	-813K

Fiscal Period: December	2021	2022	2023	2024	2025
Profitability
Return on Assets	-7.01	-22.25	-30.39	-38.74	-2.07
Return on Total Capital	-8.93	-28.42	-40.91	-60.44	-3.68
Return On Equity %	-19.16	-70.86	-109.75	-731.83	158.28
Return on Common Equity	-19.16	-70.86	-109.75	-814.67	142.92
Margin Analysis
Gross Profit Margin %	90.94	64.38	70.39	71.39	67.08
SG&A Margin	199.78	1.25K	1.09K	777.97	181.89
EBITDA Margin %	-136.26	-1.18K	-1.05K	-217.29	134.08
EBITA Margin %	-137.25	-1.19K	-1.06K	-234.47	126.2
EBIT Margin %	-137.42	-1.19K	-1.06K	-919.69	-21.38
Income From Continuing Operations Margin %	-146.16	-1.36K	-1.13K	-1.33K	-190.36
Net Income Margin %	-146.16	-1.36K	-1.13K	-1.33K	-190.36
Net Avail. For Common Margin %	-146.16	-1.36K	-1.13K	-1.33K	-190.36
Normalized Net Income Margin	-96.57	-851.78	-662.95	-848.47	-112.64
Levered Free Cash Flow Margin	-181.11	-202.27	-543.8	321.57	-28.62
Unlevered Free Cash Flow Margin	-168.06	-107.46	-539.01	321.57	-21.79
Asset Turnover
Asset Turnover	0.08	0.03	0.05	0.07	0.16
Fixed Assets Turnover	1.69	0.7	1.05	1.33	2.11
Receivables Turnover (Average Receivables)	0.54	0.29	1.07	0.99	1.41
Inventory Turnover (Average Inventory)	-	-	-	-	-
Short Term Liquidity
Current Ratio	4.27	2.88	1.17	0.25	0.76
Quick Ratio	4.06	2.77	1.05	0.25	0.73
Operating Cash Flow to Current Liabilities	-1.21	-1.32	-1.67	-0.68	0.29
Days Sales Outstanding (Average Receivables)	682.02	1.26K	340.87	368.76	259.53
Days Outstanding Inventory (Average Inventory)	-	-	-	-	-
Average Days Payable Outstanding	2.77K	2.23K	2.02K	2.75K	1.62K
Cash Conversion Cycle (Average Days)	-	-	-	-	-
Long Term Solvency
Total Debt/Equity	30.16	45.51	74.31	-200.39	400.43
Total Debt / Total Capital	23.17	31.27	42.63	199.61	80.02
LT Debt/Equity	19.76	39.29	48.76	-70.32	314.64
Long-Term Debt / Total Capital	15.18	27	27.97	70.05	62.87
Total Liabilities / Total Assets	37.92	48.31	58.03	146.1	86.37
EBIT / Interest Expense	-6.58	-7.82	-138.07	-	-1.96
EBITDA / Interest Expense	-5.88	-7.58	-134.61	-	13.8
(EBITDA - Capex) / Interest Expense	-6.04	-7.8	-135.93	-	9.11
Total Debt / EBITDA	-1.99	-0.61	-0.59	-4.71	2.14
Net Debt / EBITDA	1.6	0.27	-0.23	-4.38	1.87
Total Debt / (EBITDA - Capex)	-1.94	-0.59	-0.59	-4.32	3.25
Net Debt / (EBITDA - Capex)	1.55	0.26	-0.22	-4.01	2.83
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	128.72	-64.48	24.74	-0.39	43.5
Gross Profit, 1 Yr. Growth %	158.5	-74.85	36.38	1.03	34.84
EBITDA, 1 Yr. Growth %	-28.02	207.8	11.03	-79.4	-188.55
EBITA, 1 Yr. Growth %	-27.91	206.89	11.36	-77.94	-177.24
EBIT, 1 Yr. Growth %	-28.56	206.57	11.34	-13.45	-96.66
Earnings From Cont. Operations, 1 Yr. Growth %	-645.18	229.49	4	17.63	-79.53
Net Income, 1 Yr. Growth %	-645.18	229.49	4	17.63	-79.53
Normalized Net Income, 1 Yr. Growth %	-23.11	213.35	-2.91	27.49	-80.95
Diluted EPS Before Extra, 1 Yr. Growth %	-799.99	164.28	-18.66	6.34	-87.5
Accounts Receivable, 1 Yr. Growth %	28.13	-82.72	28.24	-8.73	12.24
Inventory, 1 Yr. Growth %	-	-	-	-	-
Net Property, Plant and Equip., 1 Yr. Growth %	-12.69	-15.65	-18.97	-23.35	7.94
Total Assets, 1 Yr. Growth %	14.1	-18.8	-18.13	-49.17	-15.03
Tangible Book Value, 1 Yr. Growth %	35.62	-71.71	-177.27	442.04	-83.92
Common Equity, 1 Yr. Growth %	13.45	-32.4	-33.52	-160.32	-123.25
Cash From Operations, 1 Yr. Growth %	83.24	10.16	96.94	-28.36	-114.76
Capital Expenditures, 1 Yr. Growth %	16.81	251.08	-62.5	75.27	313.17
Levered Free Cash Flow, 1 Yr. Growth %	-18.02	-60.33	235.36	-158.91	-112.77
Unlevered Free Cash Flow, 1 Yr. Growth %	-18.48	-77.29	525.69	-159.43	-109.73
Compound Annual Growth Rate Over Two Years
Total Revenues, 2 Yr. CAGR %	-2.68	-9.86	-33.43	11.47	19.56
Gross Profit, 2 Yr. CAGR %	-3.16	-19.37	-41.43	17.38	16.72
EBITDA, 2 Yr. CAGR %	-23.92	48.84	84.87	-52.18	-57.29
EBITA, 2 Yr. CAGR %	-24.55	48.74	84.87	-50.43	-58.72
EBIT, 2 Yr. CAGR %	-24.51	47.99	84.75	-1.84	-83.01
Earnings From Cont. Operations, 2 Yr. CAGR %	-58.04	323.83	85.11	10.6	-50.93
Net Income, 2 Yr. CAGR %	-58.04	323.83	85.11	10.6	-50.93
Normalized Net Income, 2 Yr. CAGR %	-26.15	55.22	74.42	11.25	-50.72
Diluted EPS Before Extra, 2 Yr. CAGR %	-64.43	330.1	46.61	-7	-63.54
Accounts Receivable, 2 Yr. CAGR %	59.46	-52.95	-52.93	8.18	1.21
Inventory, 2 Yr. CAGR %	-	-	-	-	-
Net Property, Plant and Equip., 2 Yr. CAGR %	-11.05	-14.18	-17.33	-21.19	-9.04
Total Assets, 2 Yr. CAGR %	18.75	-3.75	-18.47	-35.49	-34.28
Tangible Book Value, 2 Yr. CAGR %	315.28	-38.05	-53.24	104.66	-6.63
Common Equity, 2 Yr. CAGR %	38.4	-12.42	-32.96	-36.68	-62.55
Cash From Operations, 2 Yr. CAGR %	5.52	42.08	47.29	14.87	-67.48
Capital Expenditures, 2 Yr. CAGR %	131.22	102.51	14.74	-19.15	169.11
Levered Free Cash Flow, 2 Yr. CAGR %	24.63	-42.97	15.35	40.55	-72.57
Unlevered Free Cash Flow, 2 Yr. CAGR %	29.22	-56.97	19.21	92.83	-75.96
Compound Annual Growth Rate Over Three Years
Total Revenues, 3 Yr. CAGR %	-12.8	-30.45	0.45	-23.86	21.26
Gross Profit, 3 Yr. CAGR %	-14.51	-38.22	-3.93	-29.76	22.93
EBITDA, 3 Yr. CAGR %	-29.13	21.23	34.99	-11.05	-41.28
EBITA, 3 Yr. CAGR %	-29.1	20.44	35.06	-8.98	-42.53
EBIT, 3 Yr. CAGR %	-29.07	20.44	34.6	43.49	-68.21
Earnings From Cont. Operations, 3 Yr. CAGR %	-14.2	-16.6	165.34	59.15	-36.97
Net Income, 3 Yr. CAGR %	-14.2	-16.6	165.34	59.15	-36.97
Normalized Net Income, 3 Yr. CAGR %	-17.46	19.55	32.75	57.12	-38.22
Diluted EPS Before Extra, 3 Yr. CAGR %	-27.01	-30.59	146.87	31.73	-52.36
Accounts Receivable, 3 Yr. CAGR %	79.3	-23.98	-34.28	-41.31	9.52
Inventory, 3 Yr. CAGR %	-	-	-	-	-
Net Property, Plant and Equip., 3 Yr. CAGR %	96.24	-12.61	-15.81	-19.38	-12.48
Total Assets, 3 Yr. CAGR %	-5.69	4.62	-8.8	-30.35	-29.29
Tangible Book Value, 3 Yr. CAGR %	-16.26	69.61	-33.32	5.82	-12.34
Common Equity, 3 Yr. CAGR %	-10.14	9	-20.11	-35.28	-54.66
Cash From Operations, 3 Yr. CAGR %	-8.7	7.04	58.41	13.28	-42.04
Capital Expenditures, 3 Yr. CAGR %	45.64	165.76	15.43	31.9	39.26
Levered Free Cash Flow, 3 Yr. CAGR %	-18.09	-14.9	2.94	-7.8	-36.81
Unlevered Free Cash Flow, 3 Yr. CAGR %	-19.34	-27.61	5.03	-5.47	-28.76
Compound Annual Growth Rate Over Five Years
Total Revenues, 5 Yr. CAGR %	-1.69	-31.41	-21.73	-16.01	7.7
Gross Profit, 5 Yr. CAGR %	-0.4	-36.32	-26.51	-20.13	3.85
EBITDA, 5 Yr. CAGR %	-23.63	-0.41	3.99	-16.44	-14.81
EBITA, 5 Yr. CAGR %	-24.79	-2.27	4.02	-15.56	-15.93
EBIT, 5 Yr. CAGR %	-24.77	-2.26	4.02	10.98	-41.18
Earnings From Cont. Operations, 5 Yr. CAGR %	-23.51	-19.83	16.7	-6.63	35.08
Net Income, 5 Yr. CAGR %	-23.51	-19.83	16.7	-6.63	35.08
Normalized Net Income, 5 Yr. CAGR %	-22.26	-0.01	11.34	16.16	-10.69
Diluted EPS Before Extra, 5 Yr. CAGR %	-32.02	-30.85	-3.52	-21.97	14.87
Accounts Receivable, 5 Yr. CAGR %	40.67	21.69	5.02	-12.46	-21.89
Inventory, 5 Yr. CAGR %	-	-	-	-	-
Net Property, Plant and Equip., 5 Yr. CAGR %	25.69	40.55	38.87	-16.15	-13.16
Total Assets, 5 Yr. CAGR %	-15.76	-11.21	-11.02	-13.78	-20.01
Tangible Book Value, 5 Yr. CAGR %	16.7	-32.39	-33.67	82.85	-23.7
Common Equity, 5 Yr. CAGR %	-18.93	-14.89	-20.08	-12.28	-41
Cash From Operations, 5 Yr. CAGR %	-13.41	-19.7	10.55	10.11	-17.03
Capital Expenditures, 5 Yr. CAGR %	-23.91	49.66	32.39	65.11	61.76
Levered Free Cash Flow, 5 Yr. CAGR %	-7.56	-24.17	-6.07	4.01	-39.35
Unlevered Free Cash Flow, 5 Yr. CAGR %	-8.47	-32.35	-5.7	7.12	-41.77